Valuation: Jade Biosciences, Inc.

Market Cap 1.49B 1.29B 1.21B 1.1B 2.07B 143B 2.1B 14.22B 5.57B 71.47B 5.6B 5.48B 238B P/E 2026 *
-8.11x
P/E 2027 * -8.17x
Enterprise Value 1.15B 990M 931M 846M 1.59B 110B 1.61B 10.92B 4.28B 54.9B 4.3B 4.21B 183B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.21%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day-1.30%
1 week+3.89%
Current month+17.57%
1 month+18.05%
3 months+5.50%
6 months+60.58%
Current year+50.49%
1 week 21.51
Extreme 21.51
25
1 month 18.54
Extreme 18.54
25
Current year 12.45
Extreme 12.45
28
1 year 6.71
Extreme 6.71
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 2025-04-27
Director of Finance/CFO 38 2025-07-13
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 50 2025-04-27
Director/Board Member 42 2025-04-27
Chairman 57 2025-04-27
Date Insider Type Main position Quantity % Market Cap.
6/25/26 Free

Director

47,675 0.0966%
2/12/26 Free

General Counsel

196,875 0.4280%
2/12/26 Free

Chief Technology Officer

288,750 0.6277%
Change 5-day change 1-year change 3-year change Capi.($)
-1.30%+3.89%+209.60% - 1.49B
-0.11%-1.67%+1.80%+19.90% 48.84B
+0.96%+4.12%+487.16%+622.55% 45.44B
+1.91%+2.64%+15.48%+91.01% 41.22B
+0.58%-0.50%+26.02%+13.39% 39.71B
-2.74%-2.74%+17.30%+56.10% 32.6B
+1.28%-1.00% - - 16.25B
-1.20%-2.65%+27.34%+136.08% 16.67B
-0.49%-0.34%+3.45%+29.14% 14.08B
-1.65%-0.31%+79.08%+41.34% 13.68B
Average -0.26%+0.09%+96.36%+126.19% 27B
Weighted average by Cap. +0.09%-0.79%+103.88%+153.09%

Financials

2026 *2027 *
Net sales - -
Net income -204M -176M -166M -151M -284M -19.57B -288M -1.95B -763M -9.79B -767M -750M -32.6B -231M -200M -188M -171M -321M -22.15B -326M -2.2B -863M -11.08B -868M -849M -36.89B
Net Debt -346M -299M -281M -255M -480M -33.12B -487M -3.3B -1.29B -16.57B -1.3B -1.27B -55.18B -354M -306M -287M -261M -491M -33.89B -499M -3.37B -1.32B -16.95B -1.33B -1.3B -56.46B
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
26-08-18 US$23.22 -0.98% 332,782
26-08-17 US$23.45 -5.10% 671,571
26-08-14 US$24.71 +3.78% 1,478,444
26-08-13 US$23.81 +2.59% 1,089,591
26-08-12 US$23.21 +3.85% 713,872
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
23.45USD
Average target price
50.12USD
Spread / Average Target
+113.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock